Entrada Therapeutics(TRDA)

Focus: Entrada Therapeutics is a Boston-based public biotech specializing in delivering biologics to the cytosol, addressing rare diseases across neurology, ophthalmology, and gastroenterology. The company is early-stage with a focused pipeline anchored in Duchenne muscular dystrophy.

Rare Diseases Neurology Ophthalmology Gastroenterology

Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

7-1 this month

Stable — net -1 jobs in 30d

4 added, 5 removed. Backfill posture.

Should You Work at Entrada Therapeutics?

AI assessment

Entrada is a scientifically differentiated, financially healthy early-stage biotech best suited for risk-tolerant professionals seeking deep technical engagement and equity upside, but with meaningful binary execution risk.

Why Work Here

Rapidly growing revenue trajectory ($129M → $211M YoY) signals scale-up phase with profitability reached in FY2025 despite only 6 active job openings.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$211M

Pipeline & Clinical Trials

Non-interventional

Mitochondrial Neurogastrointestinal Encephalomyopathy

N/A

Clinical Trials (1)

NCT04245917Natural History Study of MNGIE

N/A

Help build intelligence for Entrada Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

R&D intensity at 59% reflects deep scientific investment in novel cytosolic delivery platform—rare opportunity to build differentiated technology moat.

Heavy hiring in Clinical Operations (3 of 6 roles) indicates active trial expansion and clinical milestone catalysts on near-term horizon.

Watch Out For

Zero Phase 3 programs and only 4 total active trials create significant near-term regulatory risk; earliest catalysts are Phase 1/2 readouts with no guaranteed advancement.
Only 6 active job openings suggest very limited hiring despite revenue growth, indicating either automation of roles or conservative headcount philosophy that may constrain advancement.
Early-stage pipeline with no marketed products means career progression depends entirely on pipeline success; clinical failure could trigger restructuring.

Generated by Claude from Entrada Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ENTR-601-44

Duchenne Muscular Dystrophy (DMD)

PHASE_1_2

Clinical Trials (2)

NCT07682129Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Phase 2

NCT07037862A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Phase 1/2

ENTR-601-45

Duchenne Muscular Dystrophy (DMD)

PHASE_1_2

Clinical Trials (1)

NCT07038824A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

Phase 1/2

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Rare Diseases, Gastroenterology

Publications: 5 in PubMed

SEC Filings: 2 available

Open Roles: 7 active jobs

Therapeutic Area Focus

Rare Diseases

3 pipeline

Gastroenterology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$211M63%

R&D Spend

$125M(59%)25%

Net Income

$66M

Hiring Trend

Stable

Open Roles

Added

-2

Filled/Removed

Based on last 4 crawl cycles

Research Publications(5)

Recent peer-reviewed publications with author affiliations at this company

Enhanced antisense oligonucleotide delivery reveals that transcript turnover impacts apparent splicing rescue in myotonic dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy

2026

PMID:42163456

Targeting the Expanded TCF4/Fuchs' Endothelial Corneal Dystrophy CUG Repeat with Morpholino Peptide Conjugates.

ACS omega

2023

PMID:38024683

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Entrada Therapeutics(TRDA)

Should You Work at Entrada Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Entrada Therapeutics(10)

Open Jobs (7)

Senior Clinical Operations Contractor

Associate Director, Drug Product Development & Manufacturing

Associate Director, Analytical Development & Quality Control

Director, Regulatory Writing

Biostatistician Lead Consultant

Director, Clinical Data Management

Principal Biostatistician

Financials (FY2025)

Hiring Trend

Research Publications(5)